Specific cutaneous infiltrates in patients with haematological neoplasms: a retrospective study with 49 patients.
blastic plasmacytoid dendritic cell neoplasm
leukaemia cutis
lymphoma
plasmacytoma
skin infiltration
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
15
11
2020
received:
02
09
2020
accepted:
21
11
2020
pubmed:
7
1
2021
medline:
15
12
2021
entrez:
6
1
2021
Statut:
ppublish
Résumé
Haematological neoplasms account for around 9% of all cancers, and they are recognised as an important cause of skin infiltration. However, studies analysing cutaneous metastasis of haematological neoplasms are scarce. We describe the clinical spectrum and outcomes of specific cutaneous manifestations of leukaemias, lymphomas, multiple myeloma (MM), and blastic plasmacytoid dendritic cell neoplasm (BPDN) and make a review of the literature. Data from 49 patients diagnosed with secondary cutaneous infiltration of systemic haematological neoplasms over the last 10 years in a tertiary dermatology centre were retrospectively collected, and clinical-evolutive features were analysed. Most cases were lymphoma (44.9%, n = 22), followed by leukaemia cutis (38.8%, n = 19), secondary plasmacytoma (10.2%, n = 5) and BPDN (6.1%, n = 3). Nodules were the predominant type of lesion, and most patients presented with multiple (≥3) lesions. In 51% (n = 25) of cases, cutaneous infiltration was detected before the diagnosis of the underlying malignancy. The patients in diverse nosological groups did not differ in terms of survival (P = 0.052). We recognise the clinical heterogeneity of specific cutaneous infiltrates. The high proportion of cases in which skin involvement was key to the diagnosis of systemic malignancy emphasises the role of the dermatologist in recognising and correctly managing these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Haematological neoplasms account for around 9% of all cancers, and they are recognised as an important cause of skin infiltration. However, studies analysing cutaneous metastasis of haematological neoplasms are scarce. We describe the clinical spectrum and outcomes of specific cutaneous manifestations of leukaemias, lymphomas, multiple myeloma (MM), and blastic plasmacytoid dendritic cell neoplasm (BPDN) and make a review of the literature.
METHODS
METHODS
Data from 49 patients diagnosed with secondary cutaneous infiltration of systemic haematological neoplasms over the last 10 years in a tertiary dermatology centre were retrospectively collected, and clinical-evolutive features were analysed.
RESULTS
RESULTS
Most cases were lymphoma (44.9%, n = 22), followed by leukaemia cutis (38.8%, n = 19), secondary plasmacytoma (10.2%, n = 5) and BPDN (6.1%, n = 3). Nodules were the predominant type of lesion, and most patients presented with multiple (≥3) lesions. In 51% (n = 25) of cases, cutaneous infiltration was detected before the diagnosis of the underlying malignancy. The patients in diverse nosological groups did not differ in terms of survival (P = 0.052).
CONCLUSIONS
CONCLUSIONS
We recognise the clinical heterogeneity of specific cutaneous infiltrates. The high proportion of cases in which skin involvement was key to the diagnosis of systemic malignancy emphasises the role of the dermatologist in recognising and correctly managing these patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e228-e235Informations de copyright
© 2021 The Australasian College of Dermatologists.
Références
Smith A, Howell D, Patmore R et al. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br. J. Cancer 2011; 105: 1684-92.
Wong CYB, Helm MA, Helm TN et al. Patterns of skin metastases: A review of 25 years experience at a single cancer center. Int. J. Dermatol. 2014; 53: 56-60.
Gül Ü, Kiliç A, Gönül M et al. Spectrum of cutaneous metastases in 1287 cases of internal malignancies: A study from Turkey. Acta Derm. Venereol. 2007; 87: 160-2.
Eberle FC, Metzler G, Weisel KC et al. Cutaneous presentation of hematological malignancies. Eur. J. Dermatol. 2013; 23: 372-7.
Li AW, Yin ES, Stahl M et al. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Rev. 2017; 31: 370-88.
Wagner G, Fenchel K, Back W et al. Leukaemia cutis - Epidemiologie, Klinik und Differenzialdiagnosen. JDDG - J. Ger. Soc. Dermatol. 2012; 10: 27-37.
Lee WJ, Won KH, Won CH et al. Secondary cutaneous lymphoma: a comparative clinical features and survival outcome analysis of 106 cases according to cell lineage of lymphoma. Br. J. Dermatol. 2014; 173: 134-45.
Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas-An update 2019. Hematol. Oncol. 2019; 37(S1): 43-7.
Merlo G, Cozzani E, Canale F et al. Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department. Hematol. Oncol. 2019; 37: 285-90.
Carlesimo M, Narcisi A, Rossi A et al. Cutaneous manifestations of systemic non-Hodgkin lymphomas (NHL): Study and review of literature. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 133-41.
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-14.
Han JH, Ko YH, Kang YK et al. Characteristics of cutaneous lymphomas in Korea according to the new WHO-EORTC classification: Report of a nationwide study. Korean J. Pathol. 2014; 48: 126-32.
Oluwole OO, Zic JA, Douds JJ et al. Cutaneous manifestations and management of hematologic neoplasms. Semin. Oncol 2016; 43: 370-83.
Palacios-Álvarez I, Román-Curto C, García-Sancho AM et al. Cutaneous annular lesions as the first sign of transformation of follicular lymphoma into diffuse large B-cell lymphoma. Indian J. Dermatol. Venereol. Leprol. 2015; 81: 495-7.
Montes-Torres A, Llamas-Velasco M, Capusan TM et al. Cutaneous involvement as the first manifestation of T-lymphoblastic lymphoma and review of the literature. J. Cutan Pathol. 2019; 46: 372-5.
Cho-Vega JH, Medeiros LJ, Prieto VG et al. Leukemia cutis. Am. J. Clin. Pathol. 2008; 129: 130-42.
Wang CX, Pusic I, Anadkat MJ. Association of leukemia cutis with survival in acute myeloid leukemia. JAMA Dermatol. 2019; 155: 826-32.
Kaddu S, Zenahlik P, Beham-schmid C et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: A clinicopathologic study of 26 patients with assessment of diagnostic criteria. J. Am. Acad. Dermatol. 1999; 40: 966-78.
Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk. Lymphoma. 2007; 48: 855-65.
Cerroni L, Zenahlik P, Höfler G et al. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia a clinicopathologic and prognostic study of 42 Patients. Am. J. Surg. Pathol. 1996; 20: 1000-10.
Liu J, Bakst R, Phelps R et al. Radiation therapy for secondary cutaneous plasmacytomas. Case Rep. Hematol. 2013; 2013: 1-5.
Requena L. Afectación cutánea específica en pacientes con mieloma múltiple. Estudio clínico-patológico, inmunohistoquímico y citogenético de 40 casos. Actas Dermosifiliogr 2005; 96: 424-40.
Jurczyszyn A, Olszewska-Szopa M, Hungria V et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016; 57: 2071-6.
Pagano L, Valentini CG, Grammatico S et al. Blastic plasmacytoid dendritic cell neoplasm: Diagnostic criteria and therapeutical approaches. Br. J. Haematol. 2016; 174: 188-202.